J.Jpn. Surg. Soc.
ISSN 1880-1129

[Abstract] [Full Text PDF] （in Japanese / 1989KB） [Members Only And Two Factor Auth.]

J.Jpn. Surg. Soc.. 84(9): 970-973, 1983

Report on the annual meeting

THE TUMOR-IMMUNOLOGICAL SIGNIFICANCE OF SPLENECTOMY FOR CANCER THERAPY

The 1st Department of Surgery, Okayama University Medical School, Okayama, Japan

Hiroaki Miwa, Keimei Kojima, Tsutomu Kobayashi, Tohru Inoue, Kenji Nakamura, Minoru Moriyama, Tetsuhide Oka, Takafumi Tsurumi, Tadashi Iijima, Akira Gohchi, Naoto Moriya, Kiyoshi Hirose, Hiroshi Yamashita, Kunzo Orita

In animal experment, 5×105 MH-134 tumor cells were transplanted s.c. on the back of the C3H/He mice. Three, seven, 14 and 21 days after tumor transplantation, splenectomy or sham operation were performed and the tumor growth and survival days were examined in each group. As the results, the tumor growth was inhibited and the survival days prologed not only in the group splenectomized three days but also 21 days after tumor transplantation.
Clinically, the effect of splenectomy in combination with immunotherapy on cell-mediated immunity and the survival rates were studied in the gastric cancer patients of upper and middle stomach with 90 cases of stage III and 48 cases at stage IV, totalling 138 cases who underwent total gastrectomy during 1965 and 1981. Immunotherapy was conducted with immunomodulator levamisole at a daily dose of 150 mg, three consecutive days every other week. As a result, splenctomy was not effective for advanced gastric cancer at stage III and in the patients spleen should be retained for immunotherapy. Splenectomy for gastric cancer at stage IV, particularly in combination with immunotherapy, produced augmentation of cell-mediated immunity and longer survival as well. Complications caused by splenectomy were small.

<< To previous pageTo next page >>

To read the PDF file you will need Adobe Reader installed on your computer.